Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Asthma
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Related Questions
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
